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Statement of findings
Serial plasma samples from 1006 patients with breast cancer revealed: (i) no correlation of
p53 autoantibody status with disease status at the time of sample collection, or with
menopausal status at time of primary diagnosis of breast cancer; (ii) 155 out of 1006 (15%)
of patients were positive for p53 autoantibodies, and these patients tended to have a
persistent autoantibody status throughout follow up, irrespective of disease behaviour; and
(iii) where a negative autoantibody status was found at primary diagnosis of breast cancer,
this negative status persisted throughout follow up, irrespective of later disease behaviour.
We conclude that screening for p53 autoantibody status is not informative on residual
tumour activity nor on therapeutic responsiveness.
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ELISA = enzyme-linked immunosorbent assay; OD = optical density; PBS = phosphate-buffered saline.
Introduction: Dysfunction of the tumour-suppressor protein,
p53, may be due to either mutational or epigenetic factors,
each of which may lead to accumulation of cytoplasmic p53.
Abnormal accumulation of p53 in breast cancer tissue is
predictive of poor prognosis [1,2]. Humoral studies [3,4] have
shown that cancer patients may develop immunity to
abnormally expressed p53, as revealed by p53 autoantibodies
in the blood. Again, prognostic correlates have been noted,
with presence of circulating p53 autoantibodies at diagnosis of
breast cancer being associated with reduced overall survival
[5,6] and with poor prognostic factors such as high histological
grade and the absence of hormone receptors [5,7,8].
Little is known of the potential value of p53 autoantibody in
follow up of cancer. In lung cancer there is evidence that
autoantibodies to p53 may provide a useful tool to monitor
response to therapy [9,10], whereas serial measurements of
autoantibodies to p53 in 40 patients with advanced ovarian
cancer were not found to be clinically useful [11]. In breast
cancer some 30% of node-negative patients will relapse within
5 years, but there is no current means to predict those who are
at risk.
We performed the present study to ask if the presence of
autoantibodies to p53 has any association with breast cancer
progression.
Materials and methods: A library of plasma samples were
collected from all patients attending one general oncology
clinic for postoperative follow up of breast cancer. The clinical
status of each patient at the time of sampling was summarized.
An average of eight plasma samples were cryopreserved for
each patient over a period of 15 years.
The enzyme-linked immusorbent assay (ELISA) for p53
autoantibodies was developed in-house, based on the ELISA
procedure of Lubin et al [3]. Our in-house method is detailed in
the full text of this article. In one assay series we compared a
commercial ELISA kit for p53 autoantibodies with our in-house
ELISA. A total of 20 patients’ samples were tested,
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representing a range of positive and negative readings. Two
samples scored as strongly positive with the in-house assay,
but only one of these two scored positive with the commercial
assay. Having established sensitivity, specificity and
reproducibility of the in-house assay, we judged that this was
superior to the commercial assay both in terms of sensitivity
and of cost (£1 per test compared with £23 per test). The in-
house assay was thus used throughout the present study.
Results: Serial plasma samples from 1006 patients with breast
cancer revealed the following: (i) no correlation of p53
autoantibody status with disease status at the time of sample
collection (Table 1), or with menopausal status at time of
primary diagnosis of breast cancer (Table 2); (ii) 155 out of
1006 (15%) of patients were positive for p53 autoantibodies,
and these patients tended to have a persistent autoantibody
status throughout follow up, irrespective of disease behaviour;
and (iii) where a negative autoantibody status was found at
primary diagnosis of breast cancer, this negative status
persisted throughout follow up, irrespective of later disease
behaviour (Table 3).
Discussion: As a working hypothesis, we proposed that levels
of autoantibodies to p53 would reflect tumour behaviour.
However, we found that the presence or absence of p53
autoantibodies was not predictive of presence or absence of
recurrent disease. There was an equivalent incidence of active
disease at the time of sampling in both the autoantibody-
negative and autoantibody-positive groups, these being 25.2
and 28.7%, respectively. Thus, humoral immune activity against
p53 appeared to be relatively restricted to a subgroup of
patients in whom, once an autoantibody response had been
generated, antibody was likely to persist regardless of tumour
behaviour. Conversely, where no detectable p53 autoantibody
was present at the time of primary diagnosis, these patients
remained similarly negative for antibody, irrespective of
subsequent disease activity (Table 3).
In contrast to shed markers that correlate with tumour mass,
such as CA15.3 for cancer of the breast, any tumour-related
immune response will be subject to complex regulation.
Autoantibody responses to p53 will require appropriate primary
immunization; initial low-dose antigen exposure may induce
immune tolerance and lack of response. Higher antigen doses
may activate either antibody-mediated immunity, or cellular
immunity.
In breast cancer patients, our results suggest that, once an
active humoral response against p53 is established, then this
remains active. This persistent humoral reaction may be driven
by persistent antigenic stimulation by p53 protein derived from
overexpression of p53 at distant metastatic sites; alternatively,
irradiated normal tissue may be a source of continued antigenic
stimulation, because a long-term side effect of radiation therapy
is an increased expression of p53 in normal breast tissue that
persists for several years [12]. Since the great majority of our
total patient cohort had received radiotherapy, humoral
immunity to p53 associated with primary disease might persist,
even in those patients who enter remission, due to tumour-
independent antigenic stimulation.
Loss of p53 function is known to correlate with loss of efficacy
of cancer therapy in vivo [13,14]. This raised the possibility
that autoantibodies to p53 that develop during follow up might
indicate those patients whose tumor has become resistant to
therapy. However, the present results show that, if no immunity
has been generated at the time of primary diagnosis, then later
immunity is unlikely to occur. This corresponds to the finding
that expression of p53 antigen in biopies of locally advanced
breast cancer did not correlate with drug resistance [15,16].
Table 1
Incidence of autoantibodies to p53 compared with disease
status at last clinic attendance
Disease status % Anti-p53 positive
Primary remission 14.7% (82/557)
Secondary remission 17.4% (27/155)
Secondary recurrent 19.4% (20/103)
Continuous active 16.5% (24/145)
Total 15.9% (153/96)*
Pearson χ2: P = 0.606. *Information on disease status at last sample
time was available for 960 out of 1006 patients
Table 2
Incidence of autoantibodies to p53 compared with menopausal
status at diagnosis
Menopausal status Anti-p53 positive (%)
Premenopausal 15.0% (104/693)
Postmenopausal 16.8% (51/313)
Total 15.4% (155/1006)
Pearson χ2: P = 0.788.
Table 3
Anti-p53 negative patients do not become positive with
recurrent disease
Current Anti-p53 status Current anti-p53 
disease status at diagnosis status
Nonactive disease 38/38 negative 38/38 negative
Active disease 21/22 negative 22/22 negative
Sixty patients who were negative for p53 autoantibodies had also had
a plasma sample taken within 30 days of their primary diagnosis of
breast cancer. To determine whether antibody status at diagnosis
might have been predictive of later disease behaviour (ie independent
of the current negative status), we compared two patient subgroups:
patients with current nonactive disease and patients with current active
disease. With one exception, all patients were antibody negative within
30 days of initial diagnosis. This showed that recurrent disease is
highly unlikely to induce a humoral anti-p53 response in those patients
who were initially antibody negative.
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Introduction
The tumour-suppressor protein p53 is a nuclear transcrip-
tion factor that is autoregulatory in terms of expression,
this being low in normal cells. Loss of p53 function is
often associated with high accumulation of p53 and its
retention in the cytoplasm. Abnormal accumulation of p53
in breast cancer tissue is predictive for poor prognosis
[1,2]. Humoral studies [3,4] have shown that cancer
patients may develop immunity to abnormally expressed
p53, as revealed by p53 autoantibodies in the blood.
Again, prognostic correlates have been noted, with pres-
ence of circulating p53 autoantibodies at diagnosis of
breast cancer being associated with reduced overall sur-
vival [5,6] and with poor prognostic factors such as high
histological grade and the absence of hormone receptors
[5,7,8]. P53 dysfunction may be due to either mutational
or epigenetic factors, each of which may lead to accumu-
lation of cytoplasmic p53.
Little is known of the potential value of p53 autoantibody
in follow-up of cancer. In lung cancer there is evidence
that autoantibodies to p53 may provide a useful tool to
monitor response to therapy [9,10], whereas serial mea-
surements of autoantibodies to p53 in 40 patients with
advanced ovarian cancer were not found to be clinically
useful [11]. In breast cancer, some 30% of node-negative
patients will relapse within 5 years, but there is no current
means to predict those who are at risk. We have asked if
the presence of autoantibodies to p53 have any associa-
tion with disease progression by testing plasma samples
taken from 1006 patients with breast cancer with a
median follow-up period of 4 years.
Materials and methods
Patient plasma samples
A library of plasma samples were collected from all patients
attending one general oncology clinic for postoperative
follow up of breast cancer; samples were taken without any
patient selection and irrespective of clinical stage,
menopausal status, histological type or degree of differenti-
ation. The operative management of each patient was
according to the tenets of their surgeons at the time of pre-
sentation; the breast was conserved wherever possible.
The majority of patients were treated with adjuvant radio-
therapy. Adjuvant cytotoxic chemotherapy, with or without
tamoxifen, was the subject of clinical trial at the time.
The clinical status of each patient at time of sampling had
been summarized on a database using Helix Express
(version 1.0.1; Helix Technologies, Northbrook, IL, USA).
The plasma library had been established over a 15-year
period, with an average of eight plasma samples per
patient being cryopreserved. It is known that cryopre-
served p53 autoantibodies are stable in either sera or
plasma, and that several cycles of freezing/thawing do not
cause loss of titre (Soussi T, personal communication).
Although it is theoretically possible that shed p53 protein
might partially block autoantibody in some patients, it has
already been shown [17] that autoantibody to p53 is nor-
mally in excess, and is thus detectable by ELISA.
P53 autoantibody detection by enzyme-linked
immunosorbent assay
The ELISA assay for p53 autoantibodies was developed
in-house, based on the ELISA procedure of Lubin et al [3]
in which the amount of specific p53 autoantibody
recorded by ELISA was confirmed by Western blot and
immunoprecipitation analyses. Briefly, 96-well assay plates
(Falcon 3912; Becton Dickinson and Co, Oxnard, CA,
USA) were precoated with baculoviral-derived, purified,
wild-type, full-length, human recombinant p53 (0.1 ng/ml
phosphate-buffered saline [PBS]) using 30 µl per well.
After overnight incubation at 4°C, the plates were washed
three times with PBS–0.1% Tween at room temperature.
Wells were then blocked for 2 h with 250 µl PBS–0.5%
Tween. After five washes with PBS–0.1% Tween, 30 µl of
each plasma sample was incubated on ice for 2 h. The
plate was again washed five times as above before addi-
tion of horse radish peroxidase-linked goat antiserum to
human immunoglobulin (Sigma A8667; Sigma Aldrich Co
Ltd, Poole, Dorset, UK) and incubation on ice for 1 h. After
a further five washes, bound horse radish peroxidase was
detected by conventional methods using O-phenylenedi-
amine dihydrochloride (30 min), stopping with 3 mol/l
H2SO4, and reading the optical density (OD) at 492 nm.
An OD reading of less than 0.4 was taken as a negative
result. This cutoff was determined by titration of positive
and negative samples (1/10, 1/50, 1/100 and 1/500) and
gave good discrimination between positive and negative
samples at 1/500 dilution. All assay runs included the
same internal standards of a sample known to be positive
at 1/500 dilution and a sample known to be negative at
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Overall, the present observations show that screening for p53
autoantibody status is not informative on residual tumour
activity, or on therapeutic responsiveness. We conclude that
the potential value of p53 autoantibody screening in patients
with breast cancer is limited to the prognostic information
obtained at diagnosis.
1/10 dilution, in order to confirm assay reproducibility
throughout the series.
The intial screen of all patients was at a plasma dilution of
1/10 in PBS–0.1% Tween. Samples from all patients with
a positive OD reading at the 1/10 dilution were then re-
assayed at 1/500 (see Sample processing, below). The
positive and negative internal standards ensured that all
results were directly comparable. Background controls
received no p53 protein. Specificity controls used soluble
p53 protein added to the positive plasma sample before
assay; this resulted in loss of signal.
In one assay series we compared a commercial ELISA kit
for p53 autoantibodies (produced by Dianova GmbH;
licenced to CalBiochem-Novabiochem Corp; distributed
by Oncogene Research Products, Cambridge, MA, USA;
cat no. QIA 16) with our in-house ELISA. A total of 20
patients’ samples were tested, representing a range of
positive and negative readings. Two samples were scored
strongly positive by the in-house assay, but only one of
these two scored positive by the Dianova assay. Having
established sensitivity, specificity and reproducibility of the
in-house assay, we judged that this was superior to the
commercial assay both in terms of sensitivity and of cost
(£1 per test compared with £23 per test). The in-house
assay was thus used throughout the study presented here.
Sample processing
The last sample obtained from each of the 1006 patients
was screened for anti-p53 antibodies at a 1/10 dilution.
Those patients who proved to be positive for p53 autoanti-
bodies at this low dilution were then tested for autoanti-
body status using all samples from each patient; here a
1/500 dilution of plasma was used because this was
found to give good specificity and sensitivity for known
positive and negative controls. Of those patients who
were antibody negative in the initial screen, 60 had had a
plasma sample obtained around the time of their primary
diagnosis of breast cancer; these primary samples were
assayed (1/10 dilution) to look for any positive to negative
switches in autoantibody levels during clinical follow up.
Clinical fields
The presence or absence of autoantibodies to p53 was
compared with the clinical status of each patient, which
was classified: (i) primary remission; (ii) secondary remis-
sion following a previous relapse; (iii) active relapsed
disease; or (iv) continuous active disease since first diag-
nosis. For those patients who were anti-p53 positive, their
clinical history was compared with levels of measured p53
autoantibodies throughout their follow-up period.
Results
Of the 1006 breast cancer patients screened, 155 (15%)
had autoantibodies to p53 in the most recently obtained
plasma sample. Of the total patient cohort, the disease
status corresponding to the time of collection of this
sample was known in 960 patients. Autoantibody status
was compared with disease status (Table 1). There was
no correlation with those patient groups who had known
active disease (either continuous active, or recurrent) or
with those in primary or secondary clinical remission; the
incidence of p53 autoantibody positivity was approxi-
mately 16% in all groups. The possibility that patient age
may influence humoral immunity was tested by comparing
premenopausal with postmenopausal patients; there was
no correlation with the patients’ menopausal status at
diagnosis with autoantibodies to p53 (Table 2).
For those patients whose most recent sample contained
p53 autoantibodies, all previous samples were screened.
This longitudinal review showed that autoantibody tended
to be persistent. Although preoperative plasma samples
were not available, some patients had been included in
this study from the time of their first appointment at the
oncology clinic; these samples were those that were most
likely to contain any residual p53 autoantibody associated
with the primary tumour. For those who had antibody
present at early follow up, levels tended to persist through-
out follow up. This was in contrast to those patients who
had no autoantibody detectable within 30 days of surgery
(see below). Overall, any fluctuations in autoantibody
levels within the positive patient cohort gave no consistent
pattern when compared with the clinical history of each
patient. Although there was no correlation between p53
autoantibody status and disease behaviour, in one patient
there was a strong correlation with prednisolone therapy
and a fall in p53 autoantibodies, presumably as a result of
steroid-induced immunosuppression. Shortly after steroid
treatment, the patient developed cerebral metastases
which were marked by a rapid rise in CA15.3.
Of the 851 patients who were negative for p53 autoanti-
bodies at a 1/10 plasma dilution, 60 had had a plasma
sample taken within 30 days of diagnosis of breast
cancer. Of these, 22 had current active disease and 38
had current inactive disease, at the time when the autoan-
tibody status of all 60 patients was negative. The first
sample (taken less than 30 days after diagnosis) was
screened and showed that 59 out of the 60 proved to
have also been negative for p53 autoantibodies around
the time of diagnosis (Table 3). This suggests that, if a
patient is negative for p53 autoantibodies at diagnosis of
active primary disease, then that patient is highly unlikely
to develop humoral immunity to p53, even in the presence
of recurrent disease.
Discussion
This large, single-centre study was designed to explore a
possible relationship between p53 autoantibody status
and breast cancer activity. One thousand and six patients
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with breast cancer attending a single referral center were
included in the study, irrespective of age or disease char-
acteristics at the time of primary diagnosis. The median
patient follow up was 4 years. An average of eight serial
plasma samples per patient had been cryopreserved, and
corresponding clinical information at the time of each sam-
ple’s collection had been entered into the database. This
fully documented library of over 8000 samples was used
to look for correlates between tumour behaviour and
autoantibodies to p53 during the clinical follow-up period.
Anti-p53 levels were independent of changes in tumour
status
As a working hypothesis we proposed that levels of
autoantibodies to p53 would reflect tumour behaviour.
Thus, for those patients who were positive for p53 autoan-
tibodies at diagnosis, we reasoned that surgical removal
of primary tumour might result in reduced p53 autoanti-
body levels. Should these levels then show a secondary
increase associated with relapsed disease, then increas-
ing levels of p53 autoantibodies might act as a biochemi-
cal marker of tumour progression. For those patients who
were negative for p53 autoantibodies, then, development
of recurrent disease may be associated with changes in
p53 expression within the metastatic tumour, leading to a
switch to an autoantibody-positive status.
We found that the presence or absence of p53 autoanti-
bodies was not predictive for presence or absence of
recurrent disease. There was an equivalent incidence of
active disease at the time of sampling in the autoantibody-
negative and autoantibody-positive groups, these being
25.2% and 28.7%, respectively.
We found that humoral immune activity against p53
appeared to be relatively restricted to a subgroup of
patients in whom, once an autoantibody response had
been generated, antibody was likely to persist regardless
of tumour behaviour. Thus, antibody-positive patients
without clinical recurrence remained antibody positive
throughout the follow-up period. Conversely, where no
detectable p53 autoantibody was present at the time of
primary diagnosis, these patients remained similarly nega-
tive for antibody irrespective of subsequent disease activ-
ity (Table 3).
Immune regulation and potential responsiveness to breast
cancer
In contrast to shed markers that correlate with tumour
mass, such as CA15.3 for cancer of the breast, any
tumour-related immune response will be subject to
complex regulation. Autoantibody responses to p53 will
require appropriate primary immunization. Initial low-dose
antigen exposure may induce immune tolerance and lack
of response. Higher antigen doses may activate either
antibody-mediated immunity, or cellular immunity.
In breast cancer patients, the present results suggest that,
once an active humoral response against p53 is estab-
lished, this response remains active. This persistent humoral
reaction may be driven by persistent antigenic stimulation by
p53 protein derived from overexpression of p53 at distant
metastatic sites. Alternatively, irradiated normal tissue may
be a source of continued antigenic stimulation, because a
long-term side effect of radiation therapy is an increased
expression of p53 in normal breast tissue, which persists for
several years [12]. Since the great majority of our total
patient cohort had received radiotherapy, humoral immunity
to p53 associated with primary disease might persist, even
in those patients who enter remission, due to tumour-inde-
pendent antigenic stimulation.
Loss of p53 function is known to correlate with loss of effi-
cacy of cancer therapy in vivo [13,14]. This raised the
possibility that autoantibodies to p53 that develop during
follow up might indicate those patients whose tumor has
become resistant to therapy. However, the present results
show that if no immunity has been generated at the time of
primary diagnosis, then later immunity is unlikely to occur.
This corresponds to the finding that expression of p53
antigen in biopsies of locally advanced breast cancer did
not correlate with drug resistance [15,16]. Overall, our
observations show that screening for p53 autoantibody
status is not informative on residual tumour activity, nor on
therapeutic responsiveness. We conclude that the poten-
tial value of p53 autoantibody screening in patients with
breast cancer is limited to the prognostic information
obtained at diagnosis.
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